Tokyo, Dec. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059748) titled 'Clinically Significant Outcomes, Disease Burden, Treatment and Management in Fibrosing Interstitial Lung Disease in Japan- A National Database Study' on Dec. 1.
Study Type:
Observational
Primary Sponsor:
Institute - Nippon Boehringer Ingelheim Co., Ltd
Condition:
Condition - IPF, PPF, and non-progressive ILD
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To investigate the cumulative incidences of clinically significant outcomes such as mortality (including lung transplantation), all cause hospitalisation, respiratory hospitalisation, and acute exacerbation in patients with fibrosing ILDs in Japan.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients diagnosed with at least 2 fibrosing ILD codes in different months during the patient identification period
Patients aged 20 years or older on the index date
Patients for whom data for the 12 months prior to the index date can be extracted as baseline data
Key exclusion criteria - None
Target Size - 200000
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 02 Month 13 Day
Date of IRB - 2025 Year 04 Month 25 Day
Anticipated trial start date - 2026 Year 04 Month 01 Day
Last follow-up date - 2026 Year 06 Month 01 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068322
Disclaimer: Curated by HT Syndication.
